Algunas Inc., dba Woodland Hills Compounding Pharmacy

CLOSEOUT LETTER Algunas Inc., dba Woodland Hills Compounding Pharmacy MARCS-CMS 532739 — March 25, 2020 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Via Email Recipient: Recipient Name Dr. Steven A. Levin Recipient Title CEO and Owner Algunas Inc., dba Woodland Hills Compounding Pharmacy 20631 Ventura Blvd. Suite 305 Woodland Hills , CA 91364 United States Issuing Office: Division of Pharmaceutical Quality Operations IV United States 949-608-2900 Dear Dr. Levin: The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter (WL# 532739) dated July 17, 2017. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter. You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. Sincerely, /S/ CDR Steven E Porter, Jr. Director, Division of Pharmaceutical Quality Operations IV Content current as of: 03/31/2020